Shinya Ueda

2.3k total citations · 1 hit paper
67 papers, 1.3k citations indexed

About

Shinya Ueda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Shinya Ueda has authored 67 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 25 papers in Surgery. Recurrent topics in Shinya Ueda's work include Lung Cancer Treatments and Mutations (15 papers), Gastric Cancer Management and Outcomes (12 papers) and Colorectal Cancer Treatments and Studies (8 papers). Shinya Ueda is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Gastric Cancer Management and Outcomes (12 papers) and Colorectal Cancer Treatments and Studies (8 papers). Shinya Ueda collaborates with scholars based in Japan, United States and Germany. Shinya Ueda's co-authors include Isamu Okamoto, Tomohiro Nishina, Satoshi Morita, Shuichi Hironaka, Masahiro Tsuda, Kazumasa Fujitani, Hideki Shimodaira, Narikazu Boku, Shinya Tokunaga and Kensei Yamaguchi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Diabetes.

In The Last Decade

Shinya Ueda

61 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

2013 351 citations Shuichi Hironaka, Shinya Ueda et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shinya Ueda Japan	18	728	599	419	302	253	67	1.3k
Takahiro Tsushima Japan	26	1.1k 1.5×	948 1.6×	1.2k 3.0×	204 0.7×	134 0.5×	141	2.2k
Yoshihisa Sakaguchi Japan	24	950 1.3×	590 1.0×	857 2.0×	429 1.4×	375 1.5×	104	1.9k
Yasuo Ohkura Japan	22	796 1.1×	1.1k 1.9×	717 1.7×	271 0.9×	158 0.6×	76	1.9k
Nozomu Machida Japan	20	802 1.1×	819 1.4×	429 1.0×	166 0.5×	251 1.0×	135	1.4k
Kazuto Harada Japan	26	885 1.2×	749 1.3×	1.1k 2.6×	521 1.7×	161 0.6×	129	2.3k
Isamu Makino Japan	23	470 0.6×	711 1.2×	585 1.4×	363 1.2×	114 0.5×	136	1.6k
Paolo Castellano Italy	21	642 0.9×	1.0k 1.7×	485 1.2×	383 1.3×	121 0.5×	32	1.7k
Yoshio Gunji Japan	17	375 0.5×	405 0.7×	374 0.9×	254 0.8×	115 0.5×	46	1.2k
Ryosuke Amano Japan	29	767 1.1×	1.5k 2.5×	936 2.2×	327 1.1×	72 0.3×	140	2.4k
Henk H. Hartgrink Netherlands	26	1.2k 1.6×	632 1.1×	791 1.9×	466 1.5×	349 1.4×	60	2.3k

Countries citing papers authored by Shinya Ueda

Since Specialization

Citations

This map shows the geographic impact of Shinya Ueda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinya Ueda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinya Ueda more than expected).

Fields of papers citing papers by Shinya Ueda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinya Ueda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinya Ueda. The network helps show where Shinya Ueda may publish in the future.

Co-authorship network of co-authors of Shinya Ueda

This figure shows the co-authorship network connecting the top 25 collaborators of Shinya Ueda. A scholar is included among the top collaborators of Shinya Ueda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinya Ueda. Shinya Ueda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ota, Yosuke, Takeshi Kodaira, Hirofumi Fujii, et al.. (2022). Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2). International Journal of Clinical Oncology. 27(11). 1675–1683. 2 indexed citations

Yokota, Tomoya, Yosuke Ota, Hirofumi Fujii, et al.. (2020). Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2). International Journal of Clinical Oncology. 26(2). 316–325. 6 indexed citations

Ueda, Shinya, et al.. (2019). Optimal designs for regional bridging studies using the Bayesian power prior method. Pharmaceutical Statistics. 19(1). 22–30. 1 indexed citations

Tahara, Makoto, Naomi Kiyota, Tomoya Yokota, et al.. (2018). Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Annals of Oncology. 29(4). 1004–1009. 65 indexed citations

Shitara, Kohei, Atsuo Takashima, Kazumasa Fujitani, et al.. (2017). Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. The Lancet. Gastroenterology & hepatology. 2(4). 277–287. 139 indexed citations

Takeyama, Hiroshi, Tomoko Wakasa, Kotaro Kitani, et al.. (2017). Disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation as the first symptom of recurrent rectal cancer successfully treated with chemotherapy: A case report and review of the literature. Oncology Letters. 13(6). 4290–4294. 12 indexed citations

Ueda, Shinya, Hisato Kawakami, Shinichi Nishina, et al.. (2015). Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer. Cancer Chemotherapy and Pharmacology. 76(2). 279–285. 4 indexed citations

Imamura, Akira, et al.. (2013). Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes. Diabetes Therapy. 4(1). 41–49. 16 indexed citations

Ericsson, Hans, Daniel Röshammar, Maria Heijer, et al.. (2012). Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. International Journal of Clinical Pharmacology and Therapeutics. 50(11). 765–777. 17 indexed citations

10.

Kiyosue, Hiro, et al.. (2011). Balloon-Occluded Retrograde Transvenous Obliteration of Complex Gastric Varices Assisted by Temporary Balloon Occlusion of the Splenic Artery. Journal of Vascular and Interventional Radiology. 22(7). 1045–1048. 13 indexed citations

11.

Okamoto, Isamu, Hiroyasu Kaneda, Taroh Satoh, et al.. (2010). Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 9(10). 2825–2833. 79 indexed citations

12.

Okamoto, Isamu, Koji Takeda, Haruko Daga, et al.. (2010). Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. Lung Cancer. 70(2). 168–173. 8 indexed citations

13.

Yamazaki, Kohichi, K. Taku, Tomoya Yokota, et al.. (2010). Phase I Study of Docetaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology. 40(11). 1014–1020. 3 indexed citations

14.

Igawa, Satoshi, Nobuyuki Yamamoto, Shinya Ueda, et al.. (2007). Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer. Journal of Thoracic Oncology. 2(8). 741–744. 32 indexed citations

15.

Ohno, Tomoya, et al.. (2007). Absolute bioavailability of imidafenacin after oral administration to healthy subjects. British Journal of Clinical Pharmacology. 65(2). 197–202. 26 indexed citations

16.

Ueda, Shinya, et al.. (2002). Evaluation of capacity-limited first-pass effect through liver by three-points sampling in portal and hepatic veins and systemic artery.. Pharmaceutical Research. 19(6). 852–857. 5 indexed citations

17.

Hasegawa, T., et al.. (1998). Portal hypertensive enteropathy in biliary atresia. Pediatric Surgery International. 13(8). 602–604.

18.

Hasegawa, T., Teruhisa Sakurai, Osamu Monta, et al.. (1998). Transumbilical resection and umbilical plasty for patent omphalomesenteric duct. Pediatric Surgery International. 13(2-3). 180–181. 16 indexed citations

19.

Funama, Yoshinori, et al.. (1995). MEASUREMENT OF THE AVERAGE VALUES OVER OBSERVER'S CONFIDENCE-RATING LEVELS BY THE METHOD OF SUCCESSIVE CATEGORIES. Japanese Journal of Radiological Technology. 51(9). 1197–1202. 1 indexed citations

20.

Hori, Yuzo, et al.. (1991). [Intracranial accumulation of 99mTc-phosphorous compound on bone scintigraphy].. PubMed. 28(11). 1343–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact